Screening for Psoriatic Arthritis in Psoriasis: The Dermatologist as Gatekeeper

Welcome back to another Dermatology Times Readout 360 series. In "Screening for Psoriatic Arthritis in Psoriasis: The Dermatologist as Gatekeeper," dermatologist Bruce Strober, MD, PhD opens the Readout 360 by explaining why psoriatic arthritis is the psoriasis comorbidity clinicians are best positioned to catch.

Dr. Strober frames psoriatic arthritis as the most clinically relevant comorbidity of psoriasis, and one dermatologists can actually detect. He notes it occurs in up to 30 to 40 percent of patients with moderate-to-severe disease, and under 30 percent across all psoriasis patients. He explains that psoriatic arthritis typically appears about 10 years after the skin diagnosis. That lag, he argues, positions dermatologists as gatekeepers for early detection.

Dr. Strober cautions that predictive tools are inexact, and no single test confirms who will progress. He identifies higher-risk markers: greater body surface area involvement, obesity, and scalp, genital, or nail disease. He then contrasts how the diagnosis unfolds in rheumatology versus dermatology. Rheumatologists perform joint and ligament exams, imaging such as x-ray, ultrasound, or MRI, and supportive labs, none of which alone confirm the disease.

In his own practice, Dr. Strober screens at the first visit using a practical question battery. He asks about morning stiffness lasting more than 30 minutes, night pain, swollen or tender joints, sausage digits, painful Achilles tendons, golf or tennis elbow, plantar fasciitis, carpal tunnel, and TMJ symptoms. He also asks about family history and any prior arthritis diagnosis, and adds fatigue as an often-overlooked marker. Three or four affirmative answers, he says, raise real concern.

Dr. Strober stresses that patients frequently overlook these symptoms, so a comprehensive battery matters. He closes by warning that delayed diagnosis risks irreversible joint damage and lost function. Being slightly late treating skin is tolerable, he says, but late treatment of psoriatic arthritis carries lasting functional consequences, making early intervention essential.

Our next episode, "Modern Psoriasis Treatment: From Topicals to IL-23 and IL-17 Biologics," has Dr. Strober surveying the full range of psoriasis therapies now available.